Grades 3 and 4 adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical worsening: need for invasive mechanical ventilation, or… compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical improvement: participants discharged from hospital compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Quality of life, · individuals with moderate to severe disease
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · individuals with moderate to severe disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes clinical worsening: need for invasive mechanical ventilation, or… compared with standard plasma (very low certainty).
1 finding from 1 review
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
LD‐ICS/LABA (Direct evidence; 0 RCTs; 0 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Intervention not reported
MD‐ICS/LAMA (Direct evidence; 2 RCTs; 679 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Intervention not reported
MD‐ICS/LABA (Direct evidence; 12 RCTs; 7569 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Intervention not reported
HD‐ICS/LABA (Direct evidence; 2 RCTs; 1759 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Intervention not reported
MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 25 RCTs Total participants: 25,583 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Intervention not reported
HD‐ICS (Direct evidence; 4 RCTs; 1685 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
1 finding from 1 review
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review